The global ovarian cancer market size reached US$ 1.9 Billion in 2022. Looking forward, the analyst expects the market to reach US$ 3.7 Billion by 2028, exhibiting a growth rate (CAGR) of 11.56% during 2023-2028.
Ovarian cancer refers to a malignant tumor wherein abnormal cells in the ovary begin to multiply and grow uncontrollably from the outer tissue lining or fallopian tubes due to mutagenic changes in the deoxyribonucleic acid (DNA). At present, it can be treated with the support of various diagnoses and drugs, including antirheumatics, antineoplastics, and PARP, mitotic, and VEGF/VEGFR inhibitors. Apart from this, ovarian cancer treatment involves surgery, chemotherapy, hormone, radiation, and targeted therapies that help kill cancer cells to provide relief from signs and systems. These therapeutics are executed by medical practitioners after determining multiple factors, such as the spread of the tumor, individuals’ general health, and the size and type of ovarian cancer.
Ovarian cancer refers to a malignant tumor wherein abnormal cells in the ovary begin to multiply and grow uncontrollably from the outer tissue lining or fallopian tubes due to mutagenic changes in the deoxyribonucleic acid (DNA). At present, it can be treated with the support of various diagnoses and drugs, including antirheumatics, antineoplastics, and PARP, mitotic, and VEGF/VEGFR inhibitors. Apart from this, ovarian cancer treatment involves surgery, chemotherapy, hormone, radiation, and targeted therapies that help kill cancer cells to provide relief from signs and systems. These therapeutics are executed by medical practitioners after determining multiple factors, such as the spread of the tumor, individuals’ general health, and the size and type of ovarian cancer.
Ovarian Cancer Market Trends:
The increasing prevalence of epithelial, stromal, and germ cell ovarian cancer, especially amongst the female geriatric population, due to the genetic mutation of breast cancer gene 1 (BRCA1) or BRCA2, is primarily driving the market growth. In line with this, the rising need for effective therapeutic drugs, such as bevacizumab (Avastin) and pazopanib (Votrient), is acting as another growth-inducing factor. Additionally, the widespread adoption of combination therapies in the healthcare sector to prevent drug resistance and increase treatment efficacy is supporting the market growth. Moreover, the ongoing patent expiration of branded medications has prompted governments and pharmaceutical companies to launch novel recombinant drugs, which, in turn, is propelling market growth. Furthermore, extensive initiatives undertaken by non-governmental organizations (NGOs) to sensitize consumers regarding the symptoms, treatments, and benefits of early ovarian cancer diagnosis are impelling the market growth. Apart from this, strategic collaborations amongst key players and continuous research and development (R&D) activities to produce efficient therapeutic interventions are creating a positive outlook for the market.Key Market Segmentation
The report provides an analysis of the key trends in each sub-segment of the global ovarian cancer market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment type and end user.Breakup by Type:
- Epithelial Ovarian Cancer
- Germ Cell Ovarian Cancer
- Stromal Cell Ovarian Cancer
Breakup by Treatment Type:
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Surgery
- Others
Breakup by End User:
- Hospitals
- Homecare
- Speciality Centre
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.Key Questions Answered in This Report:
- How has the global ovarian cancer market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global ovarian cancer market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global ovarian cancer market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Ovarian Cancer Market
6 Market Breakup by Type
7 Market Breakup by Treatment Type
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- AstraZeneca plc
- Eli Lilly
- Company
- F. Hoffmann-La Roche AG
- GSK plc
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 142 |
Published | October 2023 |
Forecast Period | 2022 - 2028 |
Estimated Market Value ( USD | $ 1.9 Billion |
Forecasted Market Value ( USD | $ 3.7 Billion |
Compound Annual Growth Rate | 11.7% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |